BioLineRX
BLRX
30 hedge funds and large institutions have $5.09M invested in BioLineRX in 2021 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 9 increasing their positions, 4 reducing their positions, and 5 closing their positions.
125% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 4
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
3% more funds holding
Funds holding: 29 → 30 (+1)
0% more ownership
Funds ownership: 0.01% → 0.01% (+0%)
24% less capital invested
Capital invested by funds: $6.69M → $5.09M (-$1.6M)
47% less call options, than puts
Call options by funds: $54K | Put options by funds: $101K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAM
PVG Asset Management
Golden,
Colorado
|
+$218K |
| 2 |
Envestnet Asset Management
Chicago,
Illinois
|
+$207K |
| 3 |
JF
Jump Financial
Chicago,
Illinois
|
+$88.4K |
| 4 |
Morgan Stanley
New York
|
+$52.2K |
| 5 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
+$45.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$430K |
| 2 |
IP
Intellectus Partners
San Francisco,
California
|
-$78K |
| 3 |
SFI
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
|
-$52K |
| 4 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
-$37K |
| 5 |
FHC
First Heartland Consultants
Lake St. Louis,
Missouri
|
-$27K |
BLRX Hedge Fund Activity: Q4 2021 in Review
30 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in BioLineRX (BLRX) for Q4 2021, worth a combined $5.09M — down 24% from $6.69M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new BLRX positions and 5 closed out — a net gain of 1 holder — while 9 added to existing stakes and 4 trimmed.
The largest buyer was PVG Asset Management, adding an estimated $218K. The largest seller was Citadel Advisors, exiting entirely with an estimated $430K sold.
- 30 institutional investors held BioLineRX (BLRX) as of Q4 2021, up from 29 in Q3 2021.
- Funds reported $5.09M of BioLineRX stock for Q4 2021, down 24% quarter-over-quarter.
- 6 funds opened new BioLineRX positions in Q4 2021 and 5 closed out, a net change of +1 holder.
- The largest BioLineRX buyer in Q4 2021 was PVG Asset Management, an estimated $218K added.
- The largest BioLineRX seller in Q4 2021 was Citadel Advisors, an estimated $430K sold.
Based on aggregated 13F filings for Q4 2021.